SubHero Banner

bebtelovimab – Emergency use authorization approval

On February 11, 2022, the FDA announced the emergency use authorization (EUA) approval of Eli Lilly’s bebtelovimab, for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct severe acute respiratory symptom coronavirus 2 (SARS-CoV-2) viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate.

Download PDF